Abiomed losses narrow for Q3, bolstered by strong Impella sales

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
Abiomed, a developer of heart recovery products providing circulatory support to acute heart failure patients, trimmed losses and upped revenues for its fiscal 2009 third quarter, which ended Dec. 31, 2008.

The Danvers, Mass.-based company booked a net loss of $700,000 for the third quarter of 2009, a sharp turnaround compared with a net loss of $8.3 million in the third quarter of fiscal 2008.

The firm said its Impella (a minimally invasive, catheter-based cardiac assist device) revenue was $8.9 million, up 112 percent for the  period compared with the same quarter last year

For the quarter, the company booked total revenue of $17.3 million, up 8 percent compared with revenue of $16 million for the same period last year, according to Abiomed.